Is depression more likely with higher GLP-1 doses
Tel: +82-2-2286-1092, Fax: +82-2-921-4355, [email protected] Copyright 2014 Korean Endocrine Society This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited
After you place your order, we'll assess the destination and promptly inform you if any extra charges apply
Outcomes relied on the accuracy of diagnoses and prescriptions recorded in the database
This article briefly outlines the efficacy and safety data of the drug treatment pipeline for obesity, with a focus on incretin-based medications, and discusses the clinical challenges and significance brought about by this new era
There is no procedural downtime